for those following or participating in the E75 her2 vaccine trials at Walter Reed/PA

[Cynthia]

Lani,

You state that, "It seemed more in the vaccinated group recurred than in the control group." I draw a different conclusion from the report.

At 20 months, 5.6% of vaccinated vs. 14.2 % of control group recurred.

At 26 months, 8.3% of vaccinated vs. 14.8% of control group recurred.

I note that these numbers reach statistical significance at 20 months, but not at 26 months, though the trend seems to hold that the recurrence rate among those who received the vaccine is roughly half of the rate of the control group. This was a phase I/II study, and they are about to roll out a phase III nationwide trial very soon, if they haven't done so already.

Full disclosure, I received this vaccine and have not recurred.

Best regards,